NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 383 filers reported holding NEKTAR THERAPEUTICS in Q2 2018. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $357 | -71.9% | 508,137 | -9.5% | 0.00% | – |
| Q4 2022 | $1,270 | -99.9% | 561,727 | -13.2% | 0.00% | -100.0% |
| Q3 2022 | $2,072,000 | -17.4% | 647,431 | -1.9% | 0.00% | 0.0% |
| Q2 2022 | $2,509,000 | -4.1% | 660,178 | +43.6% | 0.00% | 0.0% |
| Q1 2022 | $2,616,000 | -58.4% | 459,759 | -1.2% | 0.00% | -50.0% |
| Q4 2021 | $6,284,000 | -28.5% | 465,113 | -5.0% | 0.00% | -33.3% |
| Q3 2021 | $8,794,000 | -0.8% | 489,686 | -5.2% | 0.00% | 0.0% |
| Q2 2021 | $8,867,000 | -14.9% | 516,726 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $10,416,000 | +14.0% | 520,793 | -3.1% | 0.00% | 0.0% |
| Q4 2020 | $9,133,000 | +3.0% | 537,242 | +0.5% | 0.00% | 0.0% |
| Q3 2020 | $8,868,000 | -29.3% | 534,555 | -1.3% | 0.00% | -40.0% |
| Q2 2020 | $12,545,000 | +21.4% | 541,681 | -6.4% | 0.01% | 0.0% |
| Q1 2020 | $10,334,000 | +41.2% | 578,965 | +6.2% | 0.01% | +66.7% |
| Q4 2019 | $7,319,000 | -25.2% | 545,094 | +1.4% | 0.00% | -25.0% |
| Q3 2019 | $9,788,000 | -70.6% | 537,348 | -42.6% | 0.00% | -69.2% |
| Q2 2019 | $33,330,000 | +14083.0% | 936,763 | +24149.6% | 0.01% | +1200.0% |
| Q3 2018 | $235,000 | -91.8% | 3,863 | -85.6% | 0.00% | -94.7% |
| Q1 2018 | $2,853,000 | +527.0% | 26,849 | +252.3% | 0.02% | +533.3% |
| Q4 2017 | $455,000 | -91.9% | 7,622 | -96.7% | 0.00% | -91.9% |
| Q3 2017 | $5,606,000 | -13.8% | 233,572 | -29.8% | 0.04% | -11.9% |
| Q2 2017 | $6,503,000 | +5144.4% | 332,609 | +3190.9% | 0.04% | +4100.0% |
| Q4 2016 | $124,000 | -97.1% | 10,107 | -96.0% | 0.00% | -96.0% |
| Q3 2016 | $4,329,000 | +175.4% | 252,002 | +93.5% | 0.02% | +150.0% |
| Q3 2014 | $1,572,000 | -19.5% | 130,245 | -14.5% | 0.01% | -16.7% |
| Q2 2014 | $1,952,000 | +4.1% | 152,248 | -1.7% | 0.01% | +9.1% |
| Q1 2014 | $1,876,000 | +139.9% | 154,813 | +124.6% | 0.01% | +120.0% |
| Q4 2013 | $782,000 | -8.9% | 68,941 | -16.1% | 0.01% | -16.7% |
| Q3 2013 | $858,000 | – | 82,173 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |